RNA Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$25.00median target· current $12.15 (+105.8%)3 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-5.020.0% YoY
Profit margin-160.0%HEALTHCARE
Market cap$207.8MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 0.89
- P/S (TTM)
- 5.67
- EV/EBITDA
- -5.72
Profitability & growth
- ROE (TTM)
- -44.0%
- Operating margin
- -88.0%
- Revenue growth YoY
- 1148.0%
- Dividend yield
- —
- Beta
- 0.93
Last earnings
May 14, 2026 · Estimate $-1.05 · Reported $-0.97
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Atrium Therapeutics, Inc. Common Stock
Company profileAvidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$207.8M
Shares outstanding$17.1M
52W high$16.77
52W low$11.40
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent